nsc 361456 has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ames, MM; Dhodapkar, MV; Reid, JM; Richardson, RL | 1 |
| Balcerzak, SP; Kraut, EH; Supko, JG | 1 |
2 trial(s) available for nsc 361456 and Neoplasms
| Article | Year |
|---|---|
Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.
Topics: Adult; Aged; Antineoplastic Agents; Drug Tolerance; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Pyrazines | 1994 |
Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Neoplasms; Pyrazines | 1993 |